A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability

References

• Yeoh TT, Tay XY, Si P, Chew L. Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J Geriatr Oncol. 2015;6(4):280–7. doi:10.1016/j.jgo.2015.05.001.
   PubMed Web of Science ®Google Scholar
• Hersh LR, Beldowski K, Hajjar ER. Polypharmacy in the geriatric oncology population. Curr Oncol Rep. 2017;19(11):73. doi:10.1007/s11912-017-0632-3.
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489–96. doi:10.1016/S1470-2045(04)01528-1.
   PubMed Web of Science ®Google Scholar
• Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage. 2014;48(6):1145–59. doi:10.1016/j.jpainsymman.2014.03.008.
   PubMed Web of Science ®Google Scholar
• Uchida M, Suzuki S, Sugawara H, Suga Y, Kokubun H, Uesawa Y, Nakagawa T, Takase H. A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan. J Pharm Health Care Sci. 2019;5(1):14. doi:10.1186/s40780-019-0143-5.
   PubMedGoogle Scholar
• Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008;24(1):175–92. doi:10.1185/030079908x253708.
   PubMed Web of Science ®Google Scholar
• Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007;9(5):298–307. doi:10.1007/s12094-007-0057-9.
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32(4):447–54. doi:10.1124/dmd.32.4.447.
   PubMed Web of Science ®Google Scholar
• Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol. 2011;67(1):63–71. doi:10.1007/s00228-010-0893-3.
   PubMed Web of Science ®Google Scholar
• Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010;70(1):78–87. doi:10.1111/j.1365-2125.2010.03653.x.
   PubMed Web of Science ®Google Scholar
• Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020;12(9):846. doi:10.3390/pharmaceutics12090846.
   PubMed Web of Science ®Google Scholar
• Amundson CJ, Knight R, Ybarra GM, Turgeon J, Bingham JM. Mitigating the risk of adverse effects related to augmentation therapy for resistant major depressive disorder: a case report. Medicina (Kaunas). 2022;58(3):438. doi:10.3390/medicina58030438.
   PubMed Web of Science ®Google Scholar
• Makihara K, Shimeda Y, Matsumura T. Influence of concomitant polypharmacy on docetaxel-induced febrile neutropenia. Cancer Diagn Progn. 2021;1(3):135–41. doi:10.21873/cdp.10018.
   PubMedGoogle Scholar
• Banerjee P, Dunkel M, Kemmler E, Preissner R. SuperCYPsPred-a web server for the prediction of cytochrome activity. Nucleic Acids Res. 2020;48(W1):W580–W585. doi:10.1093/nar/gkaa166.
   PubMed Web of Science ®Google Scholar
• Lexicomp Inc. Lexi-drugs online. Hudson: Lexicomp Inc; 2021.
   Google Scholar
• Clinical Drug Interaction Studies. Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry [U.S. Food and Drug Administration Web site]. 2020. Available at: https://www.fda.gov/media/134581/download. Accessed April 26, 2022).
   Google Scholar
• Suzuki T, Sawada T, Kawai K, Ishihara Y. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes. Life Sci. 2018;215:246–52. doi:10.1016/j.lfs.2018.07.028.
   PubMed Web of Science ®Google Scholar
• Lazzari M, Greco MT, Marcassa C, Finocchi S, Caldarulo C, Corli O. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis. Drug Des Devel Ther. 2015;9:5863–72. doi:10.2147/DDDT.S92998.
   PubMed Web of Science ®Google Scholar
• Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther. 1996;34(9):400–5.
   PubMed Web of Science ®Google Scholar
• Inoue S, Saito Y, Tsuneto S, Aruga E, Ide A, Kakurai Y. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief). J Pain Res. 2017;10:1953–62. doi:10.2147/JPR.S136937.
   PubMed Web of Science ®Google Scholar
• Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, Gyawali B, Kubo Y, Ando M, Kondo M, et al. Efficacy of Prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT): A randomized, placebo-controlled, double-blind trial. Oncologist. 2018;23(3):367–74. doi:10.1634/theoncologist.2017-0225.
   PubMed Web of Science ®Google Scholar
• Yunusa I, Gagne JJ, Yoshida K, Bykov K. Risk of opioid overdose associated with concomitant use of oxycodone and selective serotonin reuptake inhibitors. JAMA Netw Open. 2022;5(2):e220194. doi:10.1001/jamanetworkopen.2022.0194.
   PubMed Web of Science ®Google Scholar
• Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083–8. doi:10.1007/s00520-019-04884-0.
   PubMed Web of Science ®Google Scholar